Medexus Publicizes Strongest Quarter in Firm Historical past with Fiscal Q2 2023 Income of US$27.7 Million, a 55% Enhance Over Fiscal Q2 2022

Article content material

Outcomes replicate sturdy progress throughout all main prescription merchandise, together with IXINITY, Rupall, and Gleolan

Administration to host convention name at 8:00 AM Japanese Time on Wednesday, November 9, 2022

Article content material

TORONTO and CHICAGO, Nov. 08, 2022 (GLOBE NEWSWIRE) —  Medexus Prescription drugs (Medexus) (TSX: MDP) (OTCQX: MEDXF) right now introduced its working and monetary outcomes and supplied a enterprise replace for the corporate’s second fiscal quarter ended September 30, 2022. All greenback quantities on this press launch are in United States {dollars} until specified in any other case.

Commercial 2

Article content material

Monetary Highlights for Fiscal Q2 2023

  • Report whole income of $27.7 million, a year-over-year enhance of 55%, and a quarter-over-quarter enhance of 20%. This represents the strongest fiscal quarter in Medexus’s historical past. Elevated internet gross sales of IXINITY and Rupall and recognition of 100% of income from Gleolan gross sales in the USA beginning September 2022 had been sturdy contributors to this substantial year-over-year enchancment.
  • Adjusted EBITDA* of $4.2 million, a year-over-year enchancment of $6.3 million and a quarter-over-quarter enhance of $2.3 million. The first drivers for this substantial year-over-year enchancment had been will increase in revenues, a discount in analysis & improvement prices, and a rise in gross margin.
  • Working revenue of $1.9 million, a year-over-year enchancment of $6.9 million.
  • Web lack of $(2.7) million, a year-over-year change of $(12.8) million, primarily as a result of unrealized positive aspects on the change in truthful worth of the embedded derivatives in Medexus’s convertible debentures within the prior 12 months’s internet revenue.
  • Adjusted Web Loss*, which adjusts for the unrealized positive aspects and losses included in internet revenue (loss), of $2.8 million, a year-over-year enchancment of $3.3 million.
  • Money and money equivalents of $9.6 million (with $10.1 million of whole obtainable liquidity) at finish of fiscal Q2 2023.

Commercial 3

Article content material

*  Discuss with “Non-GAAP Measures” on the finish of this press launch for details about Adjusted EBITDA and Adjusted Web Earnings (Loss).

Ken d’Entremont, Chief Government Officer of Medexus, commented, “This was a wonderful quarter for Medexus, demonstrating each the robustness of our product portfolio and our initiatives to enhance margins and drive gross sales. Preliminary outcomes of our IXINITY manufacturing initiative have began to provide improved yields, which contributed to this quarter’s enhancements in our gross margins. Throughout the quarter, we delivered natural progress throughout all our main prescription merchandise, and accomplished the transition to full industrial accountability for Gleolan within the U.S. We’re excited to see Gleolan’s contribution over the approaching quarters as we execute on our industrial plan, which incorporates improved gross sales and advertising and marketing initiatives.”

Commercial 4

Article content material

Marcel Konrad, Chief Monetary Officer of Medexus, additional famous, “Throughout the second quarter we delivered a rise in our money place versus earlier quarter and generated constructive working money circulation this quarter. We additionally invested in our internet working capital, together with stock and accounts receivable, as we put together for continued progress and new enterprise, particularly because it pertains to Gleolan. We anticipate seeing the good thing about these investments in our money circulation within the coming quarters. We’re additionally actively evaluating methods to optimize our steadiness sheet and capital construction to assist this progress and have engaged third-party advisors to assist us on this initiative.”

Operational Highlights

Operational highlights for the three-month interval ended September 30, 2022 and subsequent interval embrace:

Commercial 5

Article content material

Main merchandise

  • IXINITY: Unit demand in the USA remained sturdy in the course of the quarter and elevated year-over-year, progress that was additionally mirrored within the 12 months ended September 30, 2022 – reflecting an acceleration of affected person conversions on high of a secure, present base of sufferers, following resumption of in-person promoting earlier within the 12 months. Medexus additionally continues to put money into an ongoing initiative to enhance the IXINITY manufacturing course of. Preliminary outcomes have indicated meaningfully improved yields and Medexus has began to see average enhancements in gross margins for the product.
  • Rasuvo: The corporate maintained its market main place in the course of the quarter, with an estimated 80% unit share in the course of the 12 months ended September 30, 2022, and achieved a near-record gross sales month in August, as unit demand for Rasuvo remained sturdy within the moderately-growing U.S. branded methotrexate market with a restricted gross sales drive allocation. (Supply: Symphony Sub Nationwide 9/30/2022 Knowledge & Chargebacks, PAP.) Nevertheless, rising competitors within the U.S. branded methotrexate market proceed to negatively have an effect on Rasuvo product-level income.
  • Rupall: Unit demand for the quarter elevated year-over-year given peak allergy season throughout Canada in the course of the quarter and profitable sustained execution of gross sales and advertising and marketing initiatives, which was mirrored within the unit demand progress of 25% for the 12 months ended September 30, 2022. (Supply: IQVIA CDH items – Drugstores and hospitals purchases, MAT September 2022.) This efficiency continues to place Rupall as one of many fastest-growing antihistamines within the Canadian prescription market.
  • Gleolan: Medexus acquired the unique proper to commercialize Gleolan in the USA in March 2022. Throughout the quarter Medexus efficiently accomplished the complete transition of U.S. industrial accountability to Medexus, which places the corporate in place to efficiently execute its industrial plan, together with improved gross sales and advertising and marketing initiatives. The corporate started transport Medexus-labeled product as of August, that means that September was the primary full month, and that the three-month interval ended December 31, 2022 would be the first full fiscal quarter, by which Medexus acknowledges 100% of Gleolan internet gross sales.
  • Metoject: Unit demand in Canada for the quarter elevated year-over-year, progress that was additionally mirrored within the 12 months ended September 30, 2022. Product-level efficiency continues to expertise disruption from the launch of a generic product within the Canadian methotrexate market in calendar 12 months 2020. Medexus and medac, licensor of Medexus’s commercialization rights to market and promote Metoject in Canada, proceed their joint preparations for trial within the associated patent litigation, a date for which has been set for early calendar 12 months 2023.

Commercial 6

Article content material

Product pipeline highlights

  • Treosulfan (United States): In September 2022, Medexus was knowledgeable by medac, licensor of Medexus’s commercialization rights to treosulfan, that the FDA had delivered to medac a second discover of incomplete response relating to medac’s July 2022 new drug software resubmission for treosulfan (NDA). This discover requested additional supporting data from medac to finish medac’s NDA resubmission however didn’t require submission of latest medical knowledge. Medexus will present an replace to its shareholders and different stakeholders as soon as administration is aware of whether or not the resubmission has been accepted and is best in a position to assess the influence of this delay. The corporate has utilized a lot of the infrastructure added in anticipation of a treosulfan launch to assist Gleolan, gaining expertise in lots of the identical establishments which might be anticipated to make use of treosulfan if and when it’s authorized. Medexus additionally applied a restructuring plan in October 2022 to focus sources on present merchandise.
  • IXINITY (pediatric research): Medexus continues to discover alternatives to increase the affected person inhabitants eligible to make use of IXINITY. Within the first half of calendar 12 months 2023, Medexus expects to undergo the FDA the outcomes of Medexus’s section 4 medical trial evaluating the security and efficacy of IXINITY in beforehand handled sufferers beneath 12 years of age with hemophilia B.
  • Gleolan (meningioma indication): The licensor of Medexus’s commercialization rights to Gleolan continues to pursue analysis and improvement actions relating to a meningioma indication for Gleolan (aminolevulinic acid hydrochloride or ALA HCl). Medexus’s unique commercialization rights embrace this extra meningioma indication.

Commercial 7

Article content material

Extra Info

Medexus’s monetary statements and administration’s dialogue and evaluation for the fiscal quarter ended September 30, 2022 can be found on Medexus’s company web site at and within the firm’s company filings on SEDAR at

Convention Name Particulars

Medexus will host a convention name at 8:00 AM Japanese Time on Wednesday, November 9, 2022, to debate the corporate’s working and monetary outcomes and company updates for fiscal Q2 2023.

To take part within the name, please dial the next numbers:

888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for worldwide callers

Entry code: 424091

A reside webcast of the decision will likely be obtainable on the Buyers—Information & Occasions—IR Calendar part of Medexus’s company web site or on the following hyperlink:

Commercial 8

Article content material page/2010/47041

A replay of the decision will likely be obtainable roughly one hour following the tip of the decision via Wednesday, November 16, 2022. To entry the replay, please dial the next numbers:

877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for worldwide callers

Convention ID: 47041

A replay of the webcast will likely be obtainable on the Buyers—Information & Occasions—IR Calendar part of Medexus’s company web site till Thursday, November 9, 2023.

About Medexus

Medexus is a frontrunner in revolutionary uncommon illness therapy options with a powerful North American industrial platform and a portfolio of confirmed best-in-class merchandise. Our present focus is on the therapeutic areas of hematology, auto-immune illnesses, and allergy. We proceed to construct a extremely differentiated firm with a rising portfolio of revolutionary and high-value orphan and uncommon illness merchandise that can underpin our progress for the subsequent decade.

Commercial 9

Article content material

Our present main merchandise are IXINITY®, an intravenous recombinant issue IX therapeutic to be used in sufferers 12 years of age or older with Hemophilia B (a hereditary bleeding dysfunction characterised by a deficiency of clotting issue IX within the blood, which is critical to regulate bleeding); Rasuvo™ and Metoject®, a novel formulation of methotrexate (auto-pen and pre-filled syringe) designed to deal with rheumatoid arthritis and different auto-immune illnesses; Rupall®, an revolutionary prescription allergy treatment with a novel mode of motion; and Gleolan™ (aminolevulinic acid hydrochloride or ALA HCl), an FDA-approved, orphan drug designated optical imaging agent at present indicated in sufferers with glioma (suspected World Well being Group Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue throughout surgical procedure.

Commercial 10

Article content material

We have now additionally licensed treosulfan, a part of a preparative routine for allogeneic hematopoietic stem cell transplantation for use together with fludarabine, for commercialization in the USA and Canada. Treosulfan was authorized by Well being Canada in June 2021 and is marketed in Canada as Trecondyv®. Treosulfan is at present the topic of a regulatory evaluation course of with the U.S. Meals and Drug Administration.

Our mission is to supply one of the best healthcare merchandise to healthcare professionals and sufferers. We try to ship on this mission by performing on our core values: High quality, Innovation, Buyer Service, and Collaboration.


For extra data, please contact any of the next:

Commercial 11

Article content material


Ken d’Entremont, Chief Government Officer
Medexus Prescription drugs
Tel: 905-676-0003
E-mail: [email protected]

Marcel Konrad, Chief Monetary Officer
Medexus Prescription drugs
Tel: 312-548-3139
E-mail: [email protected]

Investor Relations

Victoria Rutherford
Adelaide Capital
Tel: 1-480-625-5772
E-mail: [email protected]

Ahead-Wanting Statements

Sure statements made on this press launch include forward-looking data throughout the that means of relevant securities legal guidelines (forward-looking statements). The phrases “anticipates”, “believes”, “expects”, “will”, “plans”, “potential”, and related phrases or expressions are sometimes meant to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. Particular forward-looking statements contained on this information launch embrace, however aren’t restricted to, statements relating to Medexus’s enterprise technique or outlook and future progress plans, expectations relating to future monetary or working efficiency (together with with respect to the anticipated advantages of enhancements made to the IXINITY manufacturing course of and anticipated outcomes from gross sales of Gleolan in the USA), skill to acquire FDA approval for treosulfan, the potential for increasing the affected person inhabitants eligible for IXINITY and the timing of a associated submission to the FDA, the potential for increasing the authorized indications for Gleolan, and aggressive place of and anticipated tendencies and challenges within the firm’s enterprise and the markets by which it operates. These statements are based mostly on elements or assumptions that had been utilized in drawing a conclusion or making a forecast or projection, together with assumptions based mostly on historic tendencies, present situations and anticipated future developments. Since forward-looking statements relate to future occasions and situations, by their very nature they require making assumptions and contain inherent dangers and uncertainties. Medexus cautions that though it’s believed that the assumptions are cheap within the circumstances, these dangers and uncertainties give rise to the chance that precise outcomes could differ materially from the expectations set out within the forward-looking statements. Materials danger elements embrace these set out in Medexus’s supplies filed with the Canadian securities regulatory authorities once in a while, together with Medexus’s most up-to-date annual data kind and administration’s dialogue and evaluation; future capital necessities and dilution; mental property safety and infringement dangers; competitors (together with potential for generic competitors); reliance on key administration personnel; Medexus’s skill to implement its marketing strategy; Medexus’s skill to leverage its U.S. and Canadian infrastructure to advertise further progress; regulatory approval by related well being authorities, together with the FDA; product reimbursement by third celebration payers; litigation or expiry with respect to patents or different mental property rights; litigation danger; inventory worth volatility; authorities regulation; and potential third celebration claims. Given these dangers, undue reliance shouldn’t be positioned on these forward-looking statements, that are made solely as of the date hereof. Aside from as particularly required by regulation, Medexus undertakes no obligation to replace any forward-looking statements to replicate new data, subsequent or in any other case.

Commercial 12

Article content material

Logos and commerce names

This press launch accommodates references to logos and repair marks, together with these belonging to different firms, individuals, or entities. Solely for comfort, logos and commerce names referred to on this doc could seem with out the “®” or “™” symbols. Every such reference must be learn as if it seems with the related image. Any such references aren’t meant to point, in any means, that the holder or holders of the related mental property rights is not going to assert, to the fullest extent beneath relevant regulation, its rights to those logos and commerce names.

Non-GAAP measures

Firm administration makes use of, and this press launch refers to, monetary measures that aren’t acknowledged beneath IFRS and do not need an ordinary that means prescribed by usually accepted accounting ideas (GAAP) in accordance with IFRS or different monetary or accounting authorities (non-GAAP measures). These non-GAAP measures could embrace “non-GAAP monetary measures” and “non-GAAP ratios” (every outlined in Nationwide Instrument 52-112, Non-GAAP and Different Monetary Measures Disclosure). Medexus’s methodology for calculating these measures could differ from strategies utilized by different firms and subsequently these measures are unlikely to be corresponding to similarly-designated measures used or introduced by different firms.

Commercial 13

Article content material

Particularly, administration makes use of Adjusted Web Earnings (Loss) and Adjusted EBITDA as measures of Medexus’s efficiency. Adjusted Web Earnings (Loss), EBITDA (earnings earlier than curiosity, taxes, depreciation, and amortization) and Adjusted EBITDA are non-GAAP monetary measures. As well as, Adjusted Web Earnings (Loss) could also be introduced on a per share foundation.

An evidence and dialogue of every of those non-GAAP measures, together with their limitations, is ready out beneath the heading “Preliminary Notes—Non-GAAP measures” in Medexus’s most up-to-date administration’s dialogue and evaluation. A reconciliation of every of those non-GAAP measures to probably the most straight comparable IFRS measure will be discovered beneath the heading “Reconciliation of Adjusted Web Earnings (Loss) and Adjusted EBITDA to Web Earnings (Loss)” beneath.

Commercial 14

Article content material

Reconciliation of Adjusted Web Earnings (Loss) and Adjusted EBITDA to Web Earnings (Loss)

The next tables are derived from and must be learn along with Medexus’s consolidated assertion of operations for the three- and six-month durations ended September 30, 2022. This supplementary disclosure is meant to extra totally clarify disclosures associated to Adjusted Web Loss and Adjusted EBITDA and offers further data associated to Medexus’s working efficiency. Nevertheless, Medexus’s non-GAAP measures have limitations as analytical instruments and shouldn’t be thought of in isolation or as an alternative choice to evaluation of Medexus’s monetary data as reported beneath IFRS.

[ICWB: BB to update to current MD&A.]

Commercial 15

Article content material

(Quantities in $ ’000s) Three-month durations ended September 30 Six-month durations ended September 30
  2022   2021   2022   2021  
Web revenue (loss) (2,730 ) 10,145   (4,128 ) 3,558  
Add again:        
Unrealized acquire on truthful worth of derivatives (113 ) (16,280 ) (2,352 ) (19,526 )
Adjusted internet loss (2,843 ) (6,135 ) (6,480 ) (15,968 )
  Three-month durations ended September 30 Six-month durations ended September 30
(Quantities in $ ’000s) 2022   2021   2022   2021  
Web loss (2,730 ) 10,145   (4,128 ) 3,558  
Add again:        
Depreciation and amortization (property, gear, intangible property) 1,537   1,549   3,079   3,128  
Curiosity expense 3,293   3,072   6,442   5,956  
Earnings tax restoration 189   (2,525 ) 35   (2,525 )
EBITDA 2,289   12,241   5,428   10,117  
Add again:        
Share-based compensation 331   642   634   1,313  
Transaction-related charges 144     172   784  
Termination advantages 238   784   238    
Overseas change loss 1,308   597   1,983   384  
Unrealized acquire on truthful worth of derivatives (113 ) (16,280 ) (2,352 ) (19,526 )
Adjusted EBITDA 4,197   (2,016 ) 6,103   (6,928 )



Postmedia is dedicated to sustaining a vigorous however civil discussion board for dialogue and encourage all readers to share their views on our articles. Feedback could take as much as an hour for moderation earlier than showing on the positioning. We ask you to maintain your feedback related and respectful. We have now enabled electronic mail notifications—you’ll now obtain an electronic mail in the event you obtain a reply to your remark, there’s an replace to a remark thread you comply with or if a consumer you comply with feedback. Go to our Group Pointers for extra data and particulars on find out how to alter your electronic mail settings.

Leave a Reply